Western blotting showed that TMAO activated the MAPK pathway in prostate cancer cells, increasing phosphorylated forms of p38, JNK, and ERK, while non-phosphorylated forms decreased or remained unchanged (Figures 5D, E). Here, MAPK14 is linked to prostate carcinoma.